Introduction: Germline DICER1 mutations have recently been identified in familial multinodular goitre (MNG). The natural history of thyroid nodules in DICER1 carriers in children is unclear. The purpose of this study was to describe the clinical and genetic findings of childhood-onset MNG with DICER1 carrier in a patient who underwent total thyroidectomy. Case Presentation: The 6-year-old proband had a thyroid nodule, and the number and size of nodules increased over 3 years. A total thyroidectomy was chosen because of the rapid rise in thyroglobulin levels, discomfort when swallowing, and the mother’s history of poorly differentiated thyroid cancer (PDTC). Histopathology revealed adenomatous goitre without malignant cells. Her mother, maternal aunt, and maternal grandmother also had thyroid nodules removed during adolescence. Also, her mother had PDTC with lung metastases, and her maternal aunt had an ovarian germ cell tumour. DICER1 mutation analysis identified a heterozygous novel nonsense mutation (c.4509C>G, p.Y1503X) for the patient, her mother, her maternal grandmother, and her asymptomatic elder brother. Y1503X was identified in all resected thyroid tissues, while heterozygous D1709G, D1810V, and E1813K mutations were identified in individual nodules. Discussion/Conclusion: A thyroid nodule was detected in chemotherapy- or radiotherapy-naïve patient with DICER1 carrier aged 6 years, and MNG developed over 3 years. This pedigree highlights the natural history of nodular disease in DICER1 carriers and identifies a possible association between DICER1 and more aggressive malignancies.

1.
Francis
GL
,
Waguespack
SG
,
Bauer
AJ
,
Angelos
P
,
Benvenga
S
,
Cerutti
JM
, et al.
Management guidelines for children with thyroid nodules and differentiated thyroid cancer
.
Thyroid
.
2015 Jul
;
25
(
7
):
716
59
.
2.
Rio Frio
T
,
Bahubeshi
A
,
Kanellopoulou
C
,
Hamel
N
,
Niedziela
M
,
Sabbaghian
N
, et al.
DICER1 mutations in familial multinodular goiter with and without ovarian sertoli-leydig cell tumors
.
JAMA
.
2011 Jan
;
305
(
1
):
68
77
. .
3.
Slade
I
,
Bacchelli
C
,
Davies
H
,
Murray
A
,
Abbaszadeh
F
,
Hanks
S
, et al.
DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome
.
J Med Genet
.
2011 Apr
;
48
(
4
):
273
8
. .
4.
Khan
NE
,
Bauer
AJ
,
Schultz
KAP
,
Doros
L
,
Decastro
RM
,
Ling
A
, et al.
Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study
.
J Clin Endocrinol Metab
.
2017 May
;
102
(
5
):
1614
22
. .
5.
Kumar
MS
,
Lu
J
,
Mercer
KL
,
Golub
TR
,
Jacks
T
.
Impaired microRNA processing enhances cellular transformation and tumorigenesis
.
Nat Genet
.
2007 May
;
39
(
5
):
673
7
. .
6.
de Kock
L
,
Bah
I
,
Revil
T
,
Bérubé
P
,
Wu
MK
,
Sabbaghian
N
, et al.
Deep sequencing reveals spatially distributed distinct hot spot mutations in DICER1-related multinodular goiter
.
J Clin Endocrinol Metab
.
2016 Oct
;
101
(
10
):
3637
45
. .
7.
Rutter
MM
,
Jha
P
,
Schultz
KA
,
Sheil
A
,
Harris
AK
,
Bauer
AJ
, et al.
DICER1 mutations and differentiated thyroid carcinoma: evidence of a direct association
.
J Clin Endocrinol Metab
.
2016 Jan
;
101
(
1
):
1
5
. .
8.
Wasserman
JD
,
Sabbaghian
N
,
Fahiminiya
S
,
Chami
R
,
Mete
O
,
Acker
M
, et al.
DICER1 mutations are frequent in adolescent-onset papillary thyroid carcinoma
.
J Clin Endocrinol Metab
.
2018 May
;
103
(
5
):
2009
15
. .
9.
van der Tuin
K
,
de Kock
L
,
Kamping
EJ
,
Hannema
SE
,
Pouwels
MM
,
Niedziela
M
, et al.
Clinical and molecular characteristics may alter treatment strategies of thyroid malignancies in DICER1 syndrome
.
J Clin Endocrinol Metab
.
2019 Feb
;
104
(
2
):
277
84
. .
10.
Schultz
KAP
,
Williams
GM
,
Kamihara
J
,
Stewart
DR
,
Harris
AK
,
Bauer
AJ
, et al.
DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies
.
Clin Cancer Res
.
2018 May 15
;
24
(
10
):
2251
61
. .
11.
Chernock
RD
,
Rivera
B
,
Borrelli
N
,
Hill
DA
,
Fahiminiya
S
,
Shah
T
, et al.
Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations
.
Mod Pathol
.
2020 Jul
;
33
(
7
):
1264
74
.
Epub ahead of print
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.